<DOC>
	<DOCNO>NCT02813655</DOCNO>
	<brief_summary>The aim study assess efficacy safety Synacthène® versus placebo treatment post-dural puncture syndrome patient receive epidural analgesia , spinal analgesia , combine spinal-epidural analgesia labour .</brief_summary>
	<brief_title>Evaluation Effectiveness Tolerance Tetracosactide Synacthen® Treatment Post Dural Puncture Headaches ( ESYBRECHE )</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Post-Dural Puncture Headache</mesh_term>
	<mesh_term>Cosyntropin</mesh_term>
	<criteria>All woman receive epidural , spinal , combined spinalepidural labour analgesia present postdural puncture headache : Intense : ≥3 / 10 numerical rating pain scale Appearing within 5 day delivery Aggravating sit stand position / improve supine Can associate one follow criterion : tinnitus , nausea , photophobia , neck stiffness pain , hearing loss After exclusion clinically differential diagnosis ( preeclampsia eclampsia , cerebral venous thrombosis , migraine ) Age great equal 18 year Affiliation social security scheme Inform Consent sign oral write information Presence diplopia ( indication immediate blood patch ) Contraindication ACTH Synacthène® ( unbalanced hypertension , uncontrolled diabetes , uncontrolled psychosis , infectious viral disease state evolve ) Processing Torsade de Pointe provider ( astenizole , bepridil , erythromycin IV , halofantrine , pentamidine , sparfloxacin , sultopride , terfenadine , vincamine ) Live vaccine month prior inclusion Hypersensitivity Synacthène® Patient previously receive Synacthène® delivery Contraindication blood patch ( fever leukocytosis , HIV HCV patient ) Eclampsia preeclampsia pregnancy Patient receive prophylactic blood patch ( diagnosis Accidental Dural Puncture ) Minor 18 protect Psychological disorder allow informed consent Refusal participation study participation another ongoing interventional study Withdrawal consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tetracosactide</keyword>
	<keyword>Synacthène®</keyword>
	<keyword>cosyntropin</keyword>
	<keyword>post-dural syndrom</keyword>
	<keyword>post-dural puncture headache</keyword>
</DOC>